reagan administration soon published proposals experimental therapies more rapidly and widely available terminally ill patients pose product liability problems for drug companies experts pharmaceutical field said details proposals will published federal register shortly and will effective after day comment period under proposed policy announced tuesday commissioner food and drugs frank young press conference patients with life threatening diseases not enrolled clinical trials would allowed access experimental therapy policy also allows drug companies sell promising drugs patients previously drugs azt could rushed into wider free charge agent was effective under new policy fda could only refuse permit physician administer experimental drug was unsafe financial analysts said plan would likely benefit biotechnology companies with few products approved for marketing but would have little economic impact large drug companies with many sources revenue charging fee for still experimental drugs could help biotech companies near term financial situation and help them less dependent outside sources said teena lerner biotech analyst rothchild observers were concerned drug companies would put into legal bind promising drugs later proved have devastating side effects before lot drug companies release these drugs going have think long and hard about liability product liability problems enormous said washington based lawyer specializes drug field patients clinical trials normally sign lengthy informed consent papers before taking investigational drug lawyer said more two cases had gone trial for suits against drug company investigational drug new proposals whole new kettle fish said lawyer drug companies right now probably meeting with insurance companies burroughs wellcome arm british firm wellcome plc makes azt merck and inc hoffman laroche inc and smithkline beckman corp said was soon comment policy very uncomforable with this said wellcome spokeswoman kathy bartlett haven had chance formulate response yet early but some financial analysts proposals would benefit drug companies find proposal very significant alteration fda past policies should positively drug companies stocks said drug analyst davis saks with morgan olmstead kennedy and gardner saks also warned many health care providers would balk proposal and would call amoral charge patients with life threatening diseases for drugs otherwise would given out for free clinical trials jeffrey warren spokesman for pharmaceutical manufacturers association which represents major drug firms said mechanism already exists fda permitting certain seriously ill patients access experimental drugs and perhaps system can approved warren acknowledged pma may not able with consensus among its membership when rules formally published also admitted product liability problems could concern major drug companies jeffrey levi executive director national gay and lesbian task force which actively aids policy and funding issues cited drug suramin from bayer which had early promise aids treatment but wider clinical testing was have deadly side effects reuter 